Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
©2014 American Academy of Neurology Evidence-based Guideline: Complementary and Alternative Medicine in Multiple Sclerosis Report of the Guideline Development Subcommittee of the American Academy of Neurology ©2014 American Academy of Neurology Guideline Endorsement • This guideline was endorsed by the Consortium of Multiple Sclerosis Centers and the International Organization of Multiple Sclerosis Nurses. ©2014 American Academy of Neurology Slide 2 Authors • Vijayshree Yadav, MD, MCR • Christopher Bever Jr., MD, MBA, FAAN • James Bowen, MD • Allen Bowling, MD, PhD • Bianca Weinstock-Guttman, MD • Michelle Cameron, MD, PT • Dennis Bourdette, MD, FAAN • Gary S. Gronseth, MD, FAAN • Pushpa Narayanaswami, MBBS, DM, FAAN ©2014 American Academy of Neurology Slide 3 Sharing This Information • The American Academy of Neurology (AAN) develops these presentation slides as educational tools for neurologists and other health care practitioners. You may download and retain a single copy for your personal use. Please contact [email protected] to learn about options for sharing this content beyond your personal use. ©2014 American Academy of Neurology Slide 4 Presentation Objectives • To present the evidence since 1970 regarding complementary and alternative medicine (CAM) use in people with multiple sclerosis (MS) • To present evidence-based recommendations for CAM use in people with MS ©2014 American Academy of Neurology Slide 5 Overview • Background • Gaps in care • AAN guideline process • Analysis of evidence, conclusions, recommendations • Recommendations for future research ©2014 American Academy of Neurology Slide 6 Background • CAM use is prevalent in 33% to 80% of patients with MS,e1e10 particularly among those who are female, have higher education levels, and report poorer health.e1e4,e11 • Despite the prevalence, few patients (< 7%18%) discuss CAM use with their neurologists.e8,e12 ©2014 American Academy of Neurology Slide 7 Clinical Questions In patients with MS, 1. Do CAM therapies reduce specific symptoms and prevent relapses or disability? 2. Can CAM use worsen MS or cause serious adverse effects (SAEs)? 3. Can CAM use interfere with MS disease-modifying therapies? ©2014 American Academy of Neurology Slide 8 Clinical Questions, cont. • This guidelines addresses questions 1 and 2 together because most studies looked at all or some of these outcomes together. • No evidence was available to evaluate the effect of CAM on disease-modifying therapies (question 3). ©2014 American Academy of Neurology Slide 9 AAN Guideline Process • Clinical Question • Evidence • Conclusions • Recommendations ©2014 American Academy of Neurology Slide 10 AAN Guideline Process, cont. • Rigorous, Comprehensive, Transparent Search Search Review abstracts Review full text Relevant ©2014 American Academy of Neurology Select articles Slide 11 AAN Classification of Evidence • All studies meeting inclusion/exclusion criteria defined a priori rated Class I, II, III, or IV • Five different classification systems Therapeutic –Randomization, control, blinding Diagnostic –Comparison with reference standard Prognostic Screening Causation ©2014 American Academy of Neurology Slide 12 AAN Level of Recommendations • A = Established as effective, ineffective, or harmful (or • • • established as useful/predictive or not useful/predictive) for the given condition in the specified population B = Probably effective, ineffective, or harmful (or probably useful/predictive or not useful/predictive) for the given condition in the specified population C = Possibly effective, ineffective, or harmful (or possibly useful/predictive or not useful/predictive) for the given condition in the specified population U = Data inadequate or conflicting; given current knowledge, treatment (test, predictor) is unproven • Note that recommendations can be positive or negative ©2014 American Academy of Neurology Slide 13 Translating Class to Recommendations • A = Requires at least two consistent Class I studies* • B = Requires at least one Class I study or two consistent Class II studies • C = Requires at least one Class II study or two consistent Class III studies • U = Assigned in cases of only one Class III study, only Class IV studies, or evidence that is conflicting and cannot be reconciled * In exceptional cases, one convincing Class I study may suffice for an “A” recommendation if 1) all criteria are met, 2) the magnitude of effect is large (relative rate improved outcome > 5 and the lower limit of the confidence interval is > 2) ©2014 American Academy of Neurology Slide 14 Applying the Process to the Issue • We will now turn our attention to the guideline. ©2014 American Academy of Neurology Slide 15 Methods • Medline, Web of Science, EMBASE, Cochrane, and Allied and • • • • • Complementary Medicine Database searched (1970March 2011) Pragmatic search of Medline conducted (March 2011 to September 2013) (clinical queries filters used to identify high-quality articles that would potentially change conclusions and recommendations) Each selected article reviewed for inclusion Risk of bias determined (classification of evidence scheme for therapeutic articles) Strength of recommendations linked directly to evidence levels Conflicts of interest disclosed ©2014 American Academy of Neurology Slide 16 Literature Search/Review • Rigorous, Comprehensive, Transparent 2,608 abstracts Inclusion criteria: - Human randomized, controlled trials (RCTs); cohort studies; casecontrol studies; and case series (N ≥ 10 or addressing adverse effects [AEs]) of MS and CAM therapies that evaluated outcomes pertaining to specific MS symptoms, relapses, progression, or AEs Exclusion criteria: - 115 articles ©2014 American Academy of Neurology Case series with N < 10 Review articles Studies of nonconventional therapies excluded from the National Center for Complementary and Alternative Medicine (NCCAM)’s definition of CAM (e.g., studies of vitamin D use in MS ) Slide 17 AAN Classification of Evidence for Therapeutic Studies • Class I: A randomized, controlled clinical trial of the intervention of interest with masked or objective outcome assessment, in a representative population. Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences. The following are also required: a. b. c. d. Concealed allocation Primary outcome(s) clearly defined Exclusion/inclusion criteria clearly defined Adequate accounting for dropouts (with at least 80% of enrolled subjects completing the study) and crossovers with numbers sufficiently low to have minimal potential for bias. ©2014 American Academy of Neurology Slide 18 AAN Classification of Evidence for Therapeutic Studies, cont. e. For noninferiority or equivalence trials claiming to prove efficacy for one or both drugs, the following are also required*: –The authors explicitly state the clinically meaningful difference to be excluded by defining the threshold for equivalence or noninferiority. –The standard treatment used in the study is substantially similar to that used in previous studies establishing efficacy of the standard treatment (e.g., for a drug, the mode of administration, dose and dosage adjustments are similar to those previously shown to be effective). –The inclusion and exclusion criteria for patient selection and the outcomes of patients on the standard treatment are comparable to those of previous studies establishing efficacy of the standard treatment. –The interpretation of the results of the study is based upon a per protocol analysis that takes into account dropouts or crossovers. ©2014 American Academy of Neurology Slide 19 AAN Classification of Evidence for Therapeutic Studies, cont. • Class II: A randomized controlled clinical trial of the • intervention of interest in a representative population with masked or objective outcome assessment that lacks one criteria ae above or a prospective matched cohort study with masked or objective outcome assessment in a representative population that meets be above. Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences. Class III: All other controlled trials (including well-defined natural history controls or patients serving as own controls) in a representative population, where outcome is independently assessed, or independently derived by objective outcome measurement.** ©2014 American Academy of Neurology Slide 20 AAN Classification of Evidence for Therapeutic Studies, cont. • Class IV: Studies not meeting Class I, II, or III criteria including consensus or expert opinion. *Note that numbers 13 in Class I, item 5 are required for Class II in equivalence trials. If any one of the three is missing, the class is automatically downgraded to Class III. **Objective outcome measurement: an outcome measure that is unlikely to be affected by an observer’s (patient, treating physician, investigator) expectation or bias (e.g., blood tests, administrative outcome data). ©2014 American Academy of Neurology Slide 21 Clinical Questions 1 and 2 • In patients with MS, do CAM therapies reduce specific symptoms and prevent relapses or disability? • Can CAM use worsen MS or cause SAEs? ©2014 American Academy of Neurology Slide 22 Mind–body Medicine • Presented next are conclusions and recommendations for mindbody medicine therapies. ©2014 American Academy of Neurology Slide 23 Biofeedback Conclusion • Data are inadequate to evaluate the role of biofeedback in MS (1 Class III studye40). Recommendation • Clinicians should counsel patients with MS that the safety and efficacy of biofeedback are unknown (Level U). ©2014 American Academy of Neurology Slide 24 Hypnosis Conclusion • Data are inadequate to assess the effect of selfhypnosis (HYP), cognitive restructuring (CR), and combined HYP-CR on pain or mood (1 Class III studye41) Recommendation • Clinicians should counsel patients with MS that the safety and efficacy of HYP, CR, or HYP-CR are unknown (Level U). ©2014 American Academy of Neurology Slide 25 Music Therapy Conclusion • Data are inadequate to assess the effect of music therapy on mood (relapsing-remitting MS [RRMS], primary progressive MS, secondary progressive MS [SPMS]; 1 underpowered Class III studye42) or respiratory muscle function (chronic progressive MS, 1 underpowered Class III studye43). Recommendation • Clinicians should counsel patients with MS that the safety and efficacy of music therapy for mood or respiratory muscle function are unknown (Level U). ©2014 American Academy of Neurology Slide 26 Mindfulness-based Intervention (MBI) Conclusion • Data are inadequate to evaluate the effects of MBI on quality of life (QOL), depression, or fatigue (RRMS, SPMS, 1 Class III studye45). Recommendation • Clinicians should counsel patients with MS that the safety and efficacy of MBI for MS-related depression, fatigue, or QOL are unknown (Level U). ©2014 American Academy of Neurology Slide 27 Biologically Based Practices • Presented next are conclusions and recommendations for biologically based practices, including herbs and dietary supplementation. • Note that this guideline does not include studies of vitamin D use, as the NCCAM does not include vitamin D use in its definition of CAM. ©2014 American Academy of Neurology Slide 28 Herbs: Padma 28 Conclusion • Data are inadequate to assess the effect of Padma 28 on relapse, disability, and symptoms in MS (progressive MS, type unclear; 1 Class III studye50). Recommendation • Clinicians should counsel patients with MS that the safety and efficacy of Padma 28 for MS-related relapse, disability, or symptoms are unknown (Level U). ©2014 American Academy of Neurology Slide 29 Herbs: Ginkgo Biloba (GB) Conclusion • GB is established as ineffective for improving cognitive function in MS (2 Class I studiese51,e52). GB is possibly effective for reducing fatigue in MS (1 Class II studye53). Recommendations • Clinicians might counsel patients with MS that GB is established as ineffective for improving cognitive function in MS (Level A). • Clinicians might counsel patients with MS that GB is possibly effective for reducing fatigue in MS (Level C). ©2014 American Academy of Neurology Slide 30 Herbs: Cannabis Oral Cannabis Extract (OCE) (Containing Tetrahydrocannabinol [THC] and Cannabidiol [CBD]) and Synthetic THC Conclusions • OCE is established as effective for reducing patient-reported spasticity symptoms and pain (1215 weeks, 2 Class I studies,e55,e58 1 Class III studye67) but is probably ineffective for reducing objective spasticity measures short-term (15 weeks, 1 Class I studye55). • THC is probably effective for reducing patient-reported spasticity symptoms and pain over a period of 15 weeks (1 Class I study,e55 1 Class III studye67) but is probably ineffective for reducing objective spasticity measures short-term (15 weeks, 1 Class I studye55). • OCE and THC are possibly effective for reducing spasticity symptoms and objective spasticity measures over a 12-month period (1 Class II studye61). ©2014 American Academy of Neurology Slide 31 Herbs: Cannabis, cont. OCE (Containing THC and CBD) and Synthetic THC Conclusions, cont. • OCE and THC are probably ineffective for reducing symptoms of MS-related tremor (15 weeks, 1 Class I studye55). • Data are inadequate to support or refute the use of OCE/oral THC for overall bladder symptom severity (conflicting Class Ie55 and II studiese64), urinary urge incontinence (1 Class II study,e64 noninterpretable due to baseline imbalance between treatment groups), or the use of synthetic THC (Marinol) for central neuropathic pain (1 Class III studye66). ©2014 American Academy of Neurology Slide 32 Herbs: Cannabis, cont. OCE (Containing THC and CBD) and Synthetic THC Recommendations • Clinicians might offer OCE to patients with MS to reduce patientreported symptoms of spasticity and pain (excluding central neuropathic pain) (Level A), and might counsel patients that this symptomatic benefit is possibly maintained for 1 year (Level C). • Clinicians might offer THC to patients with MS to reduce patientreported symptoms of spasticity and pain (excluding central neuropathic pain) (Level B), and might counsel patients that this symptomatic benefit is possibly maintained for 1 year (Level C). ©2014 American Academy of Neurology Slide 33 Herbs: Cannabis, cont. OCE (Containing THC and CBD) and Synthetic THC Recommendations, cont. • Clinicians should counsel patients considering OCE or THC that, although these preparations improve spasticity-related symptoms, they are probably ineffective (short-term studies [15 weeks]) for improving objective measures of spasticity (Level B). Clinicians should counsel patients considering OCE or THC that these preparations are probably ineffective for improving tremor (Level B). • Data are inadequate to support or refute use of OCE/THC for urinary urge incontinence and overall bladder symptoms in MS (Level U). • Data are inadequate to support or refute use of synthetic THC (Marinol) for central neuropathic pain in MS (Level U). ©2014 American Academy of Neurology Slide 34 Herbs: Cannabis, cont. Sativex Oromucosal Cannabinoid Spray (Nabiximols) Conclusions • Sativex oromucosal cannabinoid spray is probably effective for improving subjective symptoms of spasticity over 6 weeks (1 Class I studye57), central neuropathic pain over 5 weeks (1 Class I studye60), and total number of bladder voids in 24 hours over 10 weeks (1 Class I studye59). • Sativex oromucosal cannabinoid spray is probably ineffective for improving objective measures of spasticity over 6 weeks (1 Class I studye57) or the number of bladder incontinence episodes over 10 weeks (1 Class I studye59). ©2014 American Academy of Neurology Slide 35 Herbs: Cannabis, cont. Sativex Oromucosal Cannabinoid Spray (Nabiximols) Conclusions, cont. • Sativex oromucosal cannabinoid spray is possibly ineffective for reducing symptoms of MS-related tremor over 15 weeks (1 Class II studye63). • Data are inadequate to support or refute the use of Sativex oromucosal cannabinoid spray for reducing overall bladder symptoms (conflicting Class I studiese57,e59,e63), anxiety symptoms or sleep problems (1 Class I study underpowered to detect benefite60), or symptoms related to cognition, QOL, or fatigue (1 Class III studye68). Data are inadequate to assess psychopathologic symptoms or abuse potential due to Sativex (1 Class III studye68). ©2014 American Academy of Neurology Slide 36 Herbs: Cannabis, cont. Sativex Oromucosal Cannabinoid Spray (Nabiximols) Recommendations • Clinicians might offer Sativex oromucosal cannabinoid spray • • (nabiximols), where available, to reduce symptoms of spasticity, pain, or urinary frequency (Level B). Clinicians should counsel patients considering Sativex oromucosal cannabinoid spray that although this preparation improves spasticity-related symptoms and urinary frequency, it is probably ineffective for improving objective measures of spasticity or the number of urinary incontinence episodes (Level B). Clinicians might choose not to offer Sativex oromucosal cannabinoid spray to reduce MS-related tremor (Level C). ©2014 American Academy of Neurology Slide 37 Herbs: Cannabis, cont. Sativex Oromucosal Cannabinoid Spray (Nabiximols) Recommendations, cont. • Data are inadequate to support or refute use of Sativex oromucosal cannabinoid spray for overall bladder symptoms, anxiety symptoms, or sleep problems, or symptoms related to cognition, QOL, or fatigue in MS (Level U). • Data are inadequate to determine the abuse potential or effect on psychopathologic symptoms of Sativex oromucosal cannabinoid spray (Level U). ©2014 American Academy of Neurology Slide 38 Herbs: Cannabis, cont. Smoked Cannabis Conclusion • Data are inadequate to determine the safety or efficacy of smoked cannabis used for spasticity and pain (1 Class III studye72), balance/posture (1 Class III studye73), and cognition (1 Class III studye72). Recommendation • Data are inadequate to support or refute use of smoked cannabis for spasticity, pain, balance/posture, or cognition in MS (Level U). ©2014 American Academy of Neurology Slide 39 Herbs: Cannabis, cont. Clinical Context • In the reviewed studies, cannabinoids were generally well • • • tolerated, although some SAEs were reported. Mild or moderate AEs were common (reported in approximately 50%80% of study subjects) and appeared to be of similar prevalence in subjects receiving cannabinoids and in those receiving a placebo control intervention. Most studies of cannabis for efficacy were of short duration, ranging from 615 weeks. No evidence was available for evaluating the safety and efficacy of smoked cannabis, although results from a single Class III studye72 suggest that decline in cognitive performance may be an SAE. ©2014 American Academy of Neurology Slide 40 Herbs: Cannabis, cont. Clinical Context, cont. • An important limitation of studies involving cannabis is the • potential for the central effects of cannabis that can potentially unmask the subjects to the treatment assignment and hence influence some of the subjective outcome results. Where details of AEs were provided, no significant attributable laboratory, hematologic, urologic, or cardiac changes were noted and no significant differences were noted in vital signs. CNS AEs (e.g., dizziness, somnolence, drowsiness, lightheadedness, memory disturbance, difficulty concentrating) were more common in subjects receiving cannabinoids than in those receiving placebo. The most common of these was dizziness, which occurred in 15% to 50% of subjects.e55,e56,e59e62,e65,e69e71 ©2014 American Academy of Neurology Slide 41 Herbs: Cannabis, cont. Clinical Context, cont. • Because cannabinoids have known psychoactive properties, their potential for psychopathological and neurocognitive AEs is a concern especially in a patient population that may be vulnerable due to underlying disorders such as MS. • Clinicians should therefore counsel patients about the potential for psychopathologic/cognitive AEs as well as other AEs associated with cannabinoids. Sativex oromucosal cannabinoid spray is not US Food and Drug Administration (FDA) approved and is not available in the United States. • In the United States, caution should be exercised with regard to the extrapolation of the results of trials of standardized OCEs (which are not commercially available) to other, nonstandardized and nonregulated, cannabis extracts (which may be commercially available in states with medical marijuana laws). ©2014 American Academy of Neurology Slide 42 Dietary Supplementation: Low-fat Diet with Omega-3 Fatty Acids Conclusion • A low-fat diet with fish oil supplementation is probably ineffective for reducing MS-related relapse, disability, or MRI lesions, or for improving fatigue or QOL symptoms (RRMS; 1 Class I study,e74 1 Class III studye76). Recommendation • Clinicians might counsel patients that a low-fat diet with fish oil (omega-3 fatty acids) supplementation is probably ineffective for reducing relapses, disability, or MRI lesions, or for improving fatigue or QOL symptoms in MS (Level B). ©2014 American Academy of Neurology Slide 43 Dietary Supplementation: Linoleic Acid Conclusion • Data are insufficient to support or refute the use of linoleic acid for reducing MS-related disability or relapse (MS type unspecified, 2 Class II studies,e77,e78 2 conflicting Class III studiese79,e80). Recommendation • Clinicians should counsel patients with MS that the safety and efficacy of linoleic acid for reducing MSrelated disability or relapse are unknown (Level U). ©2014 American Academy of Neurology Slide 44 Dietary Supplementation: Creatine Monohydrate Conclusion • Data are inadequate to support or refute the use of creatine monohydrate for improving exercise capacity short-term (5 days) in RRMS (1 underpowered Class II studye81) or in MS, type unspecified (1 underpowered Class III studye82). Recommendation • Clinicians should counsel patients with MS that the safety and efficacy of creatine monohydrate for exercise improvement shortterm are unknown (Level U). • Clinical Context. Although creatine is used most often for treatment of MS-related fatigue, no studies evaluated this effect. ©2014 American Academy of Neurology Slide 45 Dietary Supplementation: Acetyl-LCarnitine (ALCAR) Conclusion • Data are inadequate to support or refute the use of ALCAR 2 g/day for reducing MS-related fatigue (RRMS, SPMS; 1 underpowered Class II studye83). Recommendation • Clinicians should counsel patients with MS that the safety and efficacy of ALCAR for MS-related fatigue are unknown (Level U). ©2014 American Academy of Neurology Slide 46 Dietary Supplementation: Inosine Conclusion • Data are inadequate for assessing the effect of inosine on MS-related relapse rate and disability (RRMS, SPMS; conflicting Class II and III studiese84e86). Recommendation • Clinicians should counsel patients with MS that the safety and efficacy of inosine for MS-related relapse rate or disability are unknown (Level U). • Clinical Context: Inosine use is associated with kidney stone formation in 25% of patients in 1 study. ©2014 American Academy of Neurology Slide 47 Dietary Supplementation: Cari Loder Regimen Conclusion • The lofepramine plus L-phenylalanine with vitamin B12 (Cari Loder regimen) is possibly ineffective for reducing MSrelated disability, symptoms, depression, or fatigue (all MS subtypes, 1 Class II studye89). Recommendation • Clinicians might counsel patients with MS that lofepramine plus L-phenylalanine with vitamin B12 (Cari Loder regimen) is possibly ineffective for treating MS-related disability, symptoms, depression, or fatigue (Level C). ©2014 American Academy of Neurology Slide 48 Dietary Supplementation: Threonine Conclusion • Data are inadequate to evaluate the effect of threonine on MS-related spasticity and disability (progressive MS, type unspecified, 1 Class III studye90). Recommendation • Clinicians should counsel patients with MS that the safety and efficacy of threonine for MS-related spasticity or disability are unknown (Level U). ©2014 American Academy of Neurology Slide 49 Dietary Supplementation: Glucosamine Sulfate Conclusion • Data are inadequate to support or refute the use of glucosamine sulfate for reducing relapse rate or disability in RRMS (1 underpowered Class I studye91). Recommendation • Clinicians should counsel patients with MS that the safety and efficacy of glucosamine sulfate for MS-related relapse rate or disability are unknown (Level U). ©2014 American Academy of Neurology Slide 50 Dietary Supplementation: Low-dose Naltrexone (LDN) Conclusion • Data are inadequate to support or refute the use of LDN for improving QOL in RRMS and SPMS (1 Class I study,e92 1 Class II study,e93 both underpowered). Recommendation • Clinicians should counsel patients with MS that the safety and efficacy of LDN for QOL are unknown (Level U). ©2014 American Academy of Neurology Slide 51 Other Biologically Based Practices: Bee Venom Conclusion • Bee sting therapy is possibly ineffective for reducing MS-related relapses, disability, fatigue, total MRI lesion burden, new gadolinium-enhancing lesion volume, or health-related quality of life (HRQOL) (RRMS, SPMS; 1 Class II study).e94 Recommendation • Clinicians might counsel patients with MS that bee sting therapy is possibly ineffective for reducing MS-related relapses, disability, fatigue, total MRI lesion burden, new gadolinium-enhancing lesion volume, or HRQOL (Level C). • Clinical Context: Bee stings can be associated with anaphylactic reaction and possible death. ©2014 American Academy of Neurology Slide 52 Other Biologically Based Practices: Transdermal Histamine with Caffeine Conclusion • Data are inadequate to assess the effect of transdermal histamine cream on MS-related fatigue (1 Class III study).e95 Recommendation • Clinicians should counsel patients with MS that the safety and efficacy of transdermal histamine cream for MS-related fatigue are unknown (Level U). ©2014 American Academy of Neurology Slide 53 Other Biologically Based Practices: Hyperbaric Oxygen (HBO) Conclusion • Data are inadequate to assess the effect of HBO on MSrelated disability or symptoms (chronic MS, type unspecified; 1 Class 1 studye96 [control intervention made results noninterpretable], 5 Class II studies,e97e101 with inadequate power). Recommendation • Clinicians should counsel patients with MS that the safety and efficacy of HBO for MS-related disability or symptoms are unknown (Level U). ©2014 American Academy of Neurology Slide 54 Manipulative and Body-based Practices • Presented next are conclusions and recommendations for manipulative and body-based practices. ©2014 American Academy of Neurology Slide 55 Hippotherapy Conclusion • Data are inadequate to assess the effect of hippotherapy on MS-related problems with gait, balance, or mood (3 Class III studies,e107e109 2 of which were noninterpretable statisticallye107,e109). Recommendation • Clinicians should counsel patients with MS that the safety and efficacy of hippotherapy for problems with gait, balance, or mood are unknown (Level U). ©2014 American Academy of Neurology Slide 56 Reflexology Conclusions • Reflexology is possibly effective for reducing MS-associated paresthesia (MS type unspecified, 1 Class II studye111). • Data are inadequate to support or refute the use of reflexology for pain, HRQOL, disability, spasticity, fatigue, cognition, bowel/bladder function, depression, anxiety, or insomnia in MS. Recommendations • Clinicians might counsel patients with MS that reflexology is possibly effective for reducing MS-associated paresthesia (Level C). • Clinicians should counsel patients with MS that the safety and efficacy of reflexology for MS-related pain, HRQOL, disability, spasticity, fatigue, cognition, bowel/bladder function, depression, anxiety, or insomnia are unknown (Level U). ©2014 American Academy of Neurology Slide 57 Yoga Conclusion • Data are inadequate to assess the effect of yoga on MSrelated disability, spasticity, or fatigue, or on problems with cognition, mood, balance, or walking speed (MS type unspecified, 4 Class III studies,e114e117 3 underpowerede114,e117). Recommendation • Clinicians should counsel patients with MS that the safety and efficacy of yoga for MS-related disability, spasticity, or fatigue, or for problems with cognition, mood, balance, or walking speed are unknown (Level U). ©2014 American Academy of Neurology Slide 58 Massage Therapy Conclusion • Data are inadequate to evaluate the effect of massage therapy on mood, self-efficacy, constipation, pain, fatigue, balance, gait, or spasticity in MS (1 Class III study for eache118e121). Recommendation • Clinicians should counsel patients with MS that the safety and efficacy of massage therapy for mood, self-efficacy, constipation, pain, fatigue, balance, gait, or spasticity are unknown (Level U). ©2014 American Academy of Neurology Slide 59 Acupuncture Conclusion • Data are inadequate to evaluate the effect of Chinese acupuncture on QOL in SPMS or disability, QOL, or pain in RRMS (1 Class III study each,e122,e123 1 underpowerede123). Recommendation • Clinicians should counsel patients with MS that the safety and efficacy of acupuncture for QOL, disability, or pain are unknown (Level U). ©2014 American Academy of Neurology Slide 60 Progressive Muscle Relaxation Therapy (PMRT) Conclusion • Data are inadequate to evaluate the effect of PMRT on pain, disability, spasms, fatigue, cognition, depression (1 Class III studye113), or QOL (1 Class III studye124) in MS. Recommendation • Clinicians should counsel patients with MS that the safety and efficacy of PMRT on MS-related pain, disability, spasms, fatigue, cognition, depression, or QOL are unknown (Level U). ©2014 American Academy of Neurology Slide 61 Energy Medicine • Presented next are conclusions and recommendations for energy medicine therapies. ©2014 American Academy of Neurology Slide 62 Magnetic Therapy Conclusions • Magnetic therapy is probably effective for reducing fatigue in • RRMS (1 Class I study,e125 1 Class III studye128) and probably ineffective for reducing depression in RRMS (1 Class I studye125). Data are inadequate to support or refute the effectiveness of magnetic therapy for reducing MS-related disability (1 Class I studye125 with insensitive outcome measure, 1 underpowered Class II studye126), bladder control problems, or spasticity, or for improving cognition, mobility, sensation, or vision (1 underpowered Class II study,e126 3 underpowered or inconsistent Class III studiese128e130). ©2014 American Academy of Neurology Slide 63 Magnetic Therapy, cont. Recommendations • Clinicians might counsel patients with MS that magnetic therapy is probably effective for reducing fatigue (Level B) and probably ineffective for reducing depression (Level B). • Clinicians should counsel patients with MS that the safety and efficacy of magnetic therapy for reducing disability, bladder control problems, or spasticity, or for improving cognition, mobility, sensation, or vision are unknown (Level U). ©2014 American Academy of Neurology Slide 64 Neural Therapy Conclusion • Data are inadequate to assess the effect of neural therapy on MS-related disability (1 Class II studye131 with limited generalizability, 1 Class III studye131). Recommendation • Clinicians should counsel patients with MS that the safety and efficacy of neural therapy for MS-related disability are unknown (Level U). ©2014 American Academy of Neurology Slide 65 Naturopathic Medicine Conclusion • Data are inadequate to support or refute a benefit of naturopathic medicine for improving QOL, cognition, or disability, or for reducing depression or fatigue in RRMS (1 Class III studye132). Recommendation • Clinicians should counsel patients with MS that the safety and efficacy of naturopathic medicine for improving QOL, cognition, or MS-related disability, or for reducing depression or fatigue are unknown (Level U). ©2014 American Academy of Neurology Slide 66 CAM Not Reviewed (Only Class IV Studies Available) Recommendation • Clinicians should counsel patients with MS that the safety and efficacy of the following agents are unknown (Level U): 1. 2. 3. 4. 5. 6. Carnitine Chelation therapy Chinese medicine Chiropractic medicine Dental amalgam replacement Tai chi ©2014 American Academy of Neurology Slide 67 Clinical Question 3 • Does CAM use worsen MS or interferes with MS disease-modifying therapies? No evidence was available to evaluate this question. ©2014 American Academy of Neurology Slide 68 Clinical Context • CAM therapies are not regulated by the FDA. The quality control of these supplements may play a role both in their effectiveness and in their AE risk. Interactions of CAM therapies with other medications, especially disease-modifying therapies for MS, are a clinical concern. • Given the popularity of CAM therapies both in patients with MS and in patients with other neurologic disorders (e.g., Alzheimer disease, Parkinson disease), it may be useful for patients to discuss CAM treatment with neurologists and for neurologists to ask patients routinely about their CAM use. • Patients should be counseled regarding applicable quality control, safety, lack of FDA regulation of CAM, potential out-of-pocket expenses (these may not be covered by insurers), and potential drug interactions with other symptomatic and disease-modifying therapies in MS. ©2014 American Academy of Neurology Slide 69 Clinical Context, cont. Information resources for health professionals include: • National Multiple Sclerosis Society http://www.nmss.org • National Institutes of Health (NIH) http://www.nih.gov • NIH division of the National Center for Complementary and Alternative Medicines http://nccam.nih.gov ©2014 American Academy of Neurology Slide 70 Future Research Recommendations • Because the search strategy is limited only to MS, some potentially important AEs (e.g., bleeding risk with GB)e150 of the reviewed therapies noted when they were evaluated in other diseases were not apparent in the MS population. • Therapies that have received much press attention (e.g., dental amalgam removal, transdermal histamine) have little evidence to support recommendations. Most clinical trials involving CAM have methodologic flaws limiting their interpretation. • There is a need for further, rigorously designed studies of appropriate durations both for evaluating the outcomes of interest sufficiently and for using appropriate outcome measures, especially for CAM therapies that show preliminary benefits. ©2014 American Academy of Neurology Slide 71 Future Research Recommendations, cont. • Therapies such as mindbody practices, including yoga, dietary changes, and GB and antioxidant use, hold promise as research areas. • Studies of the safety and efficacy of smoked cannabis are warranted. • Studies on CAM in animal models may be useful to identify potential therapies that affect disease progression or disability and that may merit large-scale human studies; however, symptomatic effects may be difficult to evaluate in animal studies. ©2014 American Academy of Neurology Slide 72 References References cited here can be found in the full-length guideline, which is available as an online data supplement to the print publication. To locate references, please access the guideline at AAN.com/guidelines. ©2014 American Academy of Neurology Slide 73 Access the Guideline and Summary Tools • To access the complete guideline and related guideline summary tools, visit AAN.com/guidelines. ©2014 American Academy of Neurology Slide 74 Questions? ©2014 American Academy of Neurology